76-90 of 937
The Overlooked Valve: Why Women With Aortic Stenosis Fall Through the Cracks
CardiologyThe Overlooked Valve: Why Women With Aortic Stenosis Fall Through the Cracks
Pam R. Taub, MD, FACC, FASPC
Advancing Care for Women With Aortic Stenosis*: 2-Year Outcomes for Women in the 5-Year SMART Trial
CardiologyAdvancing Care for Women With Aortic Stenosis*: 2-Year Outcomes for Women in the 5-Year SMART Trial
Roxana Mehran, MD, FSCAI
Sotagliflozin in HFpEF Without Diabetes: Inside the SOTA-P-CARDIA Trial from AHA 2025
CardiologySotagliflozin in HFpEF Without Diabetes: Inside the SOTA-P-CARDIA Trial from AHA 2025
Juan Badimon, PhD, FAHA
Highlights of the Latest Hypertension Guidelines
CardiologyHighlights of the Latest Hypertension Guidelines
Clyde W. Yancy, MD
Clinical Perspective on New Therapies in Resistant Hypertension
CardiologyClinical Perspective on New Therapies in Resistant Hypertension
Clyde W. Yancy, MD
Rethinking Hormones: Testosterone and Estrogen in Women’s Heart Health
Heart MattersRethinking Hormones: Testosterone and Estrogen in Women’s Heart Health
Susan Davis
- advertisement
Targeting Vascular KCNQ5 Channels: A Promising Strategy for Blood Pressure Control
Heart MattersTargeting Vascular KCNQ5 Channels: A Promising Strategy for Blood Pressure Control
Navigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
Heart MattersNavigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
Jun-ichi Abe
Exploring Patient Perspectives on Genetic Testing for ATTR-CM
On the Frontlines of ATTR-CMExploring Patient Perspectives on Genetic Testing for ATTR-CM
Shelina Ramnarine, PhD
Quan Bui, MD
Precision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
CardiologyPrecision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
Ahmad Masri, MD, MS
The Lp(a)-Lowering Landscape: Navigating Current and Future Therapeutic Options
CardiologyThe Lp(a)-Lowering Landscape: Navigating Current and Future Therapeutic Options
Erin Michos
DARE AF Trial: Dapagliflozin to Reduce AF Burden After Catheter Ablation in Patients Without Diabetes or Heart Failure
CardiologyDARE AF Trial: Dapagliflozin to Reduce AF Burden After Catheter Ablation in Patients Without Diabetes or Heart Failure
Clyde W. Yancy, MD
- advertisement
DECAF Trial: Does Eliminating Coffee Reduce Atrial Fibrillation Recurrence in Symptomatic Patients?
CardiologyDECAF Trial: Does Eliminating Coffee Reduce Atrial Fibrillation Recurrence in Symptomatic Patients?
Christopher Wong
POLY HF Trial: A Polypill Strategy for Heart Failure With Reduced Ejection Fraction (HFrEF)
CardiologyPOLY HF Trial: A Polypill Strategy for Heart Failure With Reduced Ejection Fraction (HFrEF)
Ambarish Pandey, MD
The LDL-C-Lowering Landscape: Navigating Current and Future Therapeutic Options
CardiologyThe LDL-C-Lowering Landscape: Navigating Current and Future Therapeutic Options
Prof. Kausik Ray
